One of the largest studies of people with ATTR‑CM

studied in adults with wild-type or hereditary ATTR‑CM

The safety and effectiveness of AMVUTTRA® (vutrisiran) were studied in people with ATTR-CM. Some people in the study received AMVUTTRA and others received placebo (a treatment without any medication).

654 PEOPLE WITH ATTR-CM WERE STUDIED
  • 326 people received AMVUTTRA
  • 328 people received placebo
THE STUDY COMPARED AMVUTTRA TO PLACEBO
  • Combined risk of death and heart-related hospital visits* (through 3 years)
  • Risk of death (through 3.5 years)
  • Physical activity (at 2.5 years)
  • Health-related quality of life (at 2.5 years)
*Included hospital stays and urgent visits.

IMPORTANT SAFETY INFORMATION

What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause low vitamin A levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.  

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR‑CM) in adults to reduce heart-related death, hospital stays and urgent visits.
  • polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR‑PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Footer Waves Left Footer Waves Right